Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Short-term Investments: 2016-2024

Historic Short-term Investments for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $64.7 million.

  • UroGen Pharma's Short-term Investments fell 70.32% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 70.32%. This contributed to the annual value of $64.7 million for FY2024, which is 54.17% up from last year.
  • Latest data reveals that UroGen Pharma reported Short-term Investments of $64.7 million as of FY2024, which was up 54.17% from $42.0 million recorded in FY2023.
  • UroGen Pharma's 5-year Short-term Investments high stood at $64.7 million for FY2024, and its period low was $42.0 million during FY2023.
  • In the last 3 years, UroGen Pharma's Short-term Investments had a median value of $44.6 million in 2022 and averaged $50.4 million.
  • As far as peak fluctuations go, UroGen Pharma's Short-term Investments crashed by 49.53% in 2020, and later skyrocketed by 54.17% in 2024.
  • UroGen Pharma's Short-term Investments (Yearly) stood at $49.2 million in 2020, then decreased by 8.90% to $44.8 million in 2021, then dropped by 0.50% to $44.6 million in 2022, then dropped by 5.81% to $42.0 million in 2023, then skyrocketed by 54.17% to $64.7 million in 2024.